<DOC>
	<DOCNO>NCT01001468</DOCNO>
	<brief_summary>The purpose study examine efficacy , safety tolerability VB-201 compare placebo measure disease activity patient psoriasis .</brief_summary>
	<brief_title>Study Assess VB-201 Patients With Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Male female Patients , ≥18 ≤75 year age , diagnosis chronic plaque psoriasis least 6 month Nonanorexic subject BMI ≥20 Psoriasis Area Severity Index ( PASI ) score ≥12 Plaque psoriasis cover ≥10 % body surface area ( BSA ) Psoriasis severity least moderate , score least 3 0 5 point Physician Global Assessment ( PGA ) scale The subject present predominant type psoriasis guttate , erythrodermic , inverse , pustular palmoplantar unstable form psoriasis The subject undergone washout period sufficient duration follow treatment Baseline : Topical psoriasis treatment ; Systemic , oral inject , psoriasis treatment ; Phototherapy The subject anticipate get enough ultraviolet light study cause psoriasis improve The subject know allergy sensitivity study treatment ( ) excipients contain study drug formulation History cancer , exception skin cancer Has clinically significant systemic infection within 30 day Day 0 , history presence recurrent chronic infection Evidence tuberculosis indicate positive tuberculin skin test quantiferon test subject know + PPD negative chest xray screen History clinically significant hypoglycemia Subjects currently active peptic ulcer / gastroesophageal reflux disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Psoriasis</keyword>
</DOC>